Pulike Biological Engineering

Pulike Biological Engineering FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Pulike Biological Engineering (603566.SS) as of Oct 17, 2026 is 152.06 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 159.18 % — a change of -4.47% (lower).

FCF Conversion

152.06 %

YoY

-4.47%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Pulike Biological Engineering is 2025 152.06 % . FCF Conversion Rate (FCF/EBITDA) of Pulike Biological Engineering was 2024 159.18 % . It decreases by -4.47% lower compared to the previous year.

The Pulike Biological Engineering FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
53.57 CNY
Jan 1, 2019
50.28 CNY
Jan 1, 2020
39.09 CNY
Jan 1, 2021
-43.01 CNY
Jan 1, 2022
-76.51 CNY
Jan 1, 2023
-12.72 CNY
Jan 1, 2024
159.18 CNY
Jan 1, 2025
152.06 CNY
The Pulike Biological Engineering FCF Conversion history
YEARFCF ConversionYoY
152.06 %-4.47%
159.18 %-1,351.15%
-12.72 %-83.37%
-76.51 %+77.88%
-43.01 %-210.03%
39.09 %-22.25%
50.28 %-6.15%
53.57 %-25.01%
71.44 %-25.06%
95.34 %+128.08%
41.80 %-32.41%
61.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pulike Biological Engineering Stock analysis

What does Pulike Biological Engineering do? Pulike Biological Engineering Inc, listed on the Shanghai Stock Exchange with ticker 603566.SS and ISIN CNE1000025N0, is a pharmaceutical company based in Luoyang, China. The company went public on May 18, 2015. It employs 1,718 people and operates within the healthcare sector, specifically in the pharmaceuticals industry. Pulike Biological Engineering focuses on the research, development, manufacturing, and sale of biological products for animals, chemical drugs, and Chinese veterinary drugs. The company's veterinary biological products include vaccines and antibodies, which are used for the prevention and control of infectious diseases in poultry and livestock. Its veterinary chemical medicines are primarily used for treating epidemic diseases affecting poultry and livestock. The company is headquartered in Luoyang, Henan, and its website is http://www.pulike.com.cn/. Pulike Biological Engineering Inc is engaged in the research, development, production, and distribution of veterinary biological products and chemical medicines. The firm's product portfolio targets the prevention and treatment of diseases in animals, with a focus on poultry and livestock health management. Pulike Biological Engineering is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulike Biological Engineering stock

FCF Conversion Rate (FCF/EBITDA) of Pulike Biological Engineering is 152.06 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Pulike Biological Engineering changed from 159.18 % to 152.06 %, representing a -4.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Pulike Biological Engineering since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Pulike Biological Engineering with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Pulike Biological Engineering

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Pulike Biological Engineering